cv 3988 has been researched along with Extravascular Hemolysis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imura, Y; Kawamura, M; Nishikawa, K; Takatani, M; Terashita, Z; Tsushima, S | 1 |
| Arnout, J; De Lepeleire, I; De Schepper, P; Holmes, I; Miyamoto, Y; van Hecken, A; Vermylen, J | 1 |
1 trial(s) available for cv 3988 and Extravascular Hemolysis
| Article | Year |
|---|---|
Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Hemoglobins; Hemolysis; Humans; Injections, Intravenous; Male; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation; Random Allocation | 1988 |
1 other study(ies) available for cv 3988 and Extravascular Hemolysis
| Article | Year |
|---|---|
Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Topics: Anaphylaxis; Animals; Azepines; Furans; Hemolysis; Humans; Hypotension; Isoquinolines; Male; Microsomes; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridinium Compounds; Rabbits; Rats; Rats, Inbred Strains; Shock, Septic; Tetrahydroisoquinolines; Triazoles | 1992 |